A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ANS014004 as a Single Agent in Participants With Locally Advanced or Metastatic Solid Tumors
This is an early-stage study testing a new experimental drug called ANS014004 for people with solid tumor cancers that have spread. The goal is to see if the treatment is safe and if it shows early signs of helping to shrink or control the tumor.
This study is for adults 18 and older who are active enough to perform daily tasks and have tumors that doctors can clearly measure on scans. Participants must also have generally healthy blood, kidney, and liver function as confirmed by lab tests.
Participants will receive the new study drug and be closely monitored by a medical team to see how their body reacts to the treatment. The team will check your health regularly through physical exams, blood work, and imaging scans to track your safety and the progress of your cancer.
The study is currently recruiting new participants and is taking place at medical centers in San Diego, California; Denver, Colorado; and Orlando, Florida.
- 1This is a 'first-in-human' study, meaning it is the first time this specific drug is being tested in people.
- 2The main focus is to determine the best dose and confirm that the drug is safe for patients.
- 3People with certain serious heart conditions, active brain metastases, or untreated infections are not able to join this study.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.